T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

Trial Details

NCT ID
NCT06343311
Phase
PHASE1 / PHASE2
Sponsor
Estrella Biopharma, Inc.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • EB103
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Age 18 years or older at the time of informed consent
  • Histologically confirmed R/R B-cell non-Hodgkin's lymphoma (NHL)
  • Adequate organ function
  • Relapsed or refractory (R/R) disease defined as ONE OR MORE of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →